Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Studies cortisol and testosterone levels in men with severe obesity

Looks at hormone levels in men with severe obesity and their link to complications.

Plain-language title generated from the registry record
Registry title: Study of the Steroid Hormone Milieu in Obese Patients

Key facts

Where
Oggebbio, ItalySee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men aged 18 to 80 with severe (morbid) obesity and no other known cause of high cortisol or low testosterone.

Age
18 to 80 years
Sex
Men only
Disease stage
Severe (morbid) obesity
Earlier treatment
Cannot be using corticosteroids at the time of enrolment.

Main reasons for not taking part

  • Severe systemic illness, fever, or chronic inflammation known to cause PCR >10 mg/dL
  • Using corticosteroids at the time of enrolment
  • Poor understanding of spoken and written Italian
  • Known primary disease of the testicle
  • Known hypothalamic-pituitary or adrenal disease

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT06341699, who can take part

Where in Italy

  • Istituto Auxlogico Italiano, Hospital San Giuseppe, PiancavalloOggebbio, ItalyContact: Biagio Cangiano, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Istituto Auxologico Italiano
Trial code
NCT06341699
Record updated
13 May 2025
Original description
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity.Read full original descriptionShow less

Studio Del Milieu Steroideo in Pazienti Obesi

The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal milieu deriving from these parameters is associated with alterations in bone metabolism, lipoprotein concentration and function, and/or the severity and complications of obesity.

It will be also investigated if this hormonal milieu is a predictive factor for cardiovascular disease in obese patients.

Eligible subjects are male patients (age 18-80 years) with severe obesity and no other known causes of hypercortisolism or hypogonadism.

Questionnaires for the evaluation of mood and symptoms will be collected upon enrollment, patient's anamnestic and clinical data relating to disease complications, BMI, previous blood tests, cortisol suppression with dexamethasone 1 mg will be collected, and blood sample will be sent to and analyzed at a centralized laboratory for the study of Steroid hormones, bone metabolism, lipoprotein function, genetics and receptor analysis.

Inclusion: morbid obesity.

Exclusion: use of corticosteroids at the time of enrollment; patients suffering from severe systemic pathologies, fever, chronic inflammatory states known to cause PCR >10 mg/dL; the patient's poor understanding of spoken and written Italian; patients suffering from primary pathologies of the testicle, known at enrollment; patients suffering from hypothalamic-pituitary or adrenal pathologies already known at the time of enrollment.

ClinicalTrials.gov NCT06341699